COMMENTARY: Review: Inhaled insulin provides better glycemic control than oral hypoglycemic agents but not better than subcutaneous insulin

Punthakee, Zubin
March 2007
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p38
Academic Journal
The article presents the author's views about the study which states that inhaled insulin provides better glycemic control than oral hypoglycemic agents but not better than subcutaneous (SC) insulin. Inhaled insulin may provide better short-term diabetes control than suboptimum use of oral agents, but it is not better than SC insulin. The attractive feature of inhaled insulin is the apparent ease of administration.


Related Articles

  • oral hypoglycaemic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p413 

    The article presents information on oral hypoglycaemic drugs which are usually synthetic agents taken by mouth to reduce the levels of glucose (sugar) in the bloodstream and are used mainly in the treatment of Type II diabetes (non-insulin-dependent diabetes mellitus; maturity-onset diabetes)...

  • Synergistic Efficacy by Addition of Mitiglinide, a New Rapid Onset and Short Duration Insulin Secretagogue, to Standard Metformin for Type 2 Diabetes Mellitus (T2DM) in a Large Randomized, Double-Blind Trial. O'Brien, Richard; Scott, Russell S.; Whisnant, John K. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA553 

    Metformin has become the standard for initiation of OHA therapy after diet and exercise fail to control HbA1c in T2DM. There are several choices, however, for addition of the second OHA for patients in whom metformin yields suboptimal results. The principles of basal control of HbA1c plus...

  • Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Nathan, David M.; Buse, John B.; Davidson, Mayer B.; Ferrannini, Ele; Holman, Rury R.; Sherwin, Robert; Zinman, Bernard // Diabetes Care;Jan2009, Vol. 32 Issue 1, p193 

    The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used...

  • Early Insulin: An Important Therapeutic Strategy. Dailey III, George E. // Diabetes Care;Jan2005, Vol. 28 Issue 1, p220 

    Discusses the issue of when and how to initiate insulin in type 2 diabetes. Risk of hypoglycemia; Dose response and time to maximal effect of some treatment regimens; Duration by which the next agent should be added.

  • Incretin response in Asian type 2 diabetes: Are Indians different? Singh, Awadhesh Kumar // Indian Journal of Endocrinology & Metabolism;Jan/Feb2015, Vol. 19 Issue 1, p30 

    Incretin-based therapy has clearly emerged as one of the most sought out strategy in managing type 2 diabetes, primarily because they generally do not causes hypoglycemia and possess weight-neutral or weight losing properties. Efficacy-wise too, these agents, are more or less similar to commonly...

  • Risks of treating diabetes 2. Napoli, Maryann // Center for Medical Consumers;Aug2011, p1 

    The article discusses the risks attendant to treating type 2 diabetes. A meta-analysis, which gathered clinical results from 13 randomized tests and published in the "British Medical Journal," shows that the drugs can cause risks leading to non-fatal or fatal heart diseases for diabetics who had...

  • Third-line diabetes drugs offer comparable results.  // Pulse;5/25/2011, Vol. 71 Issue 19, p9 

    The article discusses a study on the efficiency of third-line diabetes drugs on patients with type 2 diabetes wherein researchers reveal that there is no evident difference between drug classification on patients using metformin and sulfonylurea when added with a third agent.

  • Troglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus. Plosker, G.L.; Faulds, D. // Drugs;Mar1999, Vol. 57 Issue 3, p409 

    Troglitazone is the first of a new group of oral antidiabetic drugs, the thiazolidinediones, and is indicated for the treatment of patients with type 2 (non-insulin-dependent) diabetes mellitus. Troglitazone acts by enhancing the effects of insulin at peripheral target sites and, unlike the...

  • Pioglitazone: A Viewpoint by Vivian A. Fonseca. Fonseca, V.A. // Drugs;Aug2000, Vol. 60 Issue 2, p344 

    Examines pioglitazone as a treatment for type 2 diabetes mellitus. Function of thiazolidinediones; Effect of pioglitazone on blood glucose levels; Tolerability.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics